A detailed history of Susquehanna International Group, LLP transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 406,157 shares of AMLX stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
406,157
Previous 446,038 8.94%
Holding current value
$1.64 Million
Previous $847,000 55.25%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.65 - $3.24 $65,803 - $129,214
-39,881 Reduced 8.94%
406,157 $1.32 Million
Q2 2024

Aug 15, 2024

BUY
$1.62 - $2.71 $322,767 - $539,937
199,239 Added 80.73%
446,038 $847,000
Q1 2024

May 07, 2024

SELL
$2.71 - $19.57 $856,742 - $6.19 Million
-316,141 Reduced 56.16%
246,799 $700,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $4.18 Million - $6.39 Million
346,186 Added 159.71%
562,940 $8.29 Million
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $3.5 Million - $4.54 Million
193,751 Added 842.29%
216,754 $3.97 Million
Q2 2023

Aug 11, 2023

SELL
$20.98 - $31.42 $159,594 - $239,011
-7,607 Reduced 24.85%
23,003 $496,000
Q1 2023

May 16, 2023

BUY
$27.71 - $40.93 $848,203 - $1.25 Million
30,610 New
30,610 $898,000
Q3 2022

Nov 14, 2022

SELL
$17.15 - $30.92 $2.19 Million - $3.96 Million
-127,944 Reduced 92.56%
10,285 $290,000
Q2 2022

Aug 15, 2022

BUY
$6.85 - $19.93 $627,898 - $1.83 Million
91,664 Added 196.85%
138,229 $2.66 Million
Q1 2022

May 16, 2022

BUY
$12.85 - $32.9 $598,360 - $1.53 Million
46,565 New
46,565 $598,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $237M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.